18F-labelled sodium fluoride positron emission tomography - computed tomography (PET-CT) for renal cell carcinoma (RCC)
| ISRCTN | ISRCTN66828876 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN66828876 |
| Protocol serial number | 1.2 |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust and University of Cambridge (UK) - Joint Sponsorship |
| Funder | Addenbrooke's Hospital (UK) - Radiology Department |
- Submission date
- 23/12/2010
- Registration date
- 28/04/2011
- Last edited
- 16/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Every year in the UK 6000 patients are diagnosed with renal cell carcinoma (kidney cancer). Many patients will initially present with advanced or unresectable disease (a tumor that cannot be completely removed by surgery). 30% of patients who undergo a nephrectomy (removal of a kidney) will relapse. Metastatic clear cell renal carcinoma is a type of kidney cancer that is generally resistant to chemotherapy. Metastases (tumors formed by cells that have spread) are a strong predictor of poor survival in patients with renal carcinoma. Only 0-2% of patients with advanced metastatic disease survive longer than five years, and early diagnosis and management has the potential to improve patient survival. If there are symptoms suggestive of bone metastases, then a bone scan (bone scintigraphy) is considered. Bone metastases from renal carcinoma can be poorly visualised or even missed on bone scintigraphy. In this study we will be looking at the use of a type of scan called 18F-FDG positron emission tomography (PET) for detecting bone metastases in renal cell carcinoma patients, as this type of scan has a higher sensitivity of detection.
Who can participate?
Male or female patients, 18 years of age or older, diagnosed with renal cell carcinoma.
What does the study involve?
Patients will undergo one bone scan (4 hours) and one PET/CT scan (2 hours). A bone scan is usually standard practice should a patient have signs/symptoms of possible bone metastases. Patients will receive a follow-up telephone call lasting about 15 minutes within 2 weeks of the last imaging scan. Continued follow-up will be as per standard practice.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
Addenbrookes Hospital, Cambridge (UK).
When is the study starting and how long is it expected to run for?
The study will run from March 2011 to January 2012.
Who is funding the study?
Addenbrookes Hospital, Cambridge (UK).
Who is the main contact?
Dr Ferdia Gallagher
Addenbrookes Hospital, Cambridge (UK).
Contact information
Scientific
Department of Radiology
Box 218 Level 5
Addenbrookes Hospital
Cambridge
CB2 0QQ
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single centre non-randomised non-controlled pilot feasibility study |
| Secondary study design | Non randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A pilot study investigating the sensitivity of 18F-labelled sodium fluoride positron emission tomography - computed tomography (PET-CT) for detecting skeletal metastases in renal cell carcinoma compared to planar bone scintigraphy and multidetector computed tomography (CT) |
| Study objectives | The aim of this study is to determine if 18F-labelled sodium fluoride (Na18F) positron emission tomography - computed tomography (PET-CT) is more sensitive at detecting bone metastases in renal cell carcinoma than conventional techniques i.e. planar bone scintigraphy and computed tomography (CT). Number, site, and extent of metastases will be evaluated. |
| Ethics approval(s) | Added 23/08/2011: Submitted to Brighton and Sussex REC as Cambridgeshire 2 REC did not have slots available. Approved on 12/07/2011 (ref: 11/LO/0399) |
| Health condition(s) or problem(s) studied | Renal cell carcinoma |
| Intervention | Patients will undergo one bone scan (4 hours) and one PET/CT (2 hours) scan as part of the trial. A bone scan is usually standard practice should a patient have signs/symptoms of possible bone metastases. PET/CT scan will be taken following consent and before starting treatment, if a bone scan has not previously been undertaken at Addenbrooke's Hospital, this will be completed within 28 days of the PET/CT scan. Patients will be on trial for approximately 2 months after giving consent. Patients will receive a follow up telephone call lasting approx 15 minutes within 2 weeks of the last imaging scan. Continued follow up will be as per standard practice. |
| Intervention type | Other |
| Primary outcome measure(s) |
Number of metastases detected with Na18F-PET-CT, bone scintigraphy and multidetector CT alone |
| Key secondary outcome measure(s) |
1. Site and extent of metastases detected with Na18F-PET-CT, bone scintigraphy and multidetector CT |
| Completion date | 31/01/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 20 |
| Key inclusion criteria | 1. Male or female, 18 years of age or older with no upper age limit 2. Must be able to provide a written informed consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP), national and local regulations 3. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrolment 4. Treatment-naïve patients in the first instance. If at 6 months, insufficient numbers (less than 5) can be recruited in the time period between diagnosis and treatment, then patients that have been treated will also be recruited after the first cycle of chemotherapy. 5. Life expectancy of 12 weeks or greater 6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures |
| Key exclusion criteria | 1. Diagnosis of any other malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer 2. Allergy to methylene diphosphonate used in bone scintigraphy 3. Any metabolic disorder that involves the skeletal system 4. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness 5. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrolment. 6. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or in the judgment of the investigator would make it undesirable for the patient to enter the trial 7. Not suitable to undergo a PET study, e.g., extreme obesity: greater than 226 kg |
| Date of first enrolment | 01/03/2011 |
| Date of final enrolment | 31/01/2012 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
CB2 0QQ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/10/2015 | 16/01/2019 | Yes | No |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
16/01/2019: Publication reference added
31/08/2016: No publications found in PubMed, verifying study status with principal investigator.
